Dupilumabe no tratamento de rinossinusite crônica com pólipo nasal em adolescente

Pássaro, Caroline Pinto; Dortas-Junior, Sérgio Duarte; Moreira, Nathássia da Rosa Paiva Bahiense; da-Cruz, Fabiana Chagas; Elabras-Filho, José; Ferraiolo, Priscila Novaes; Valle, Solange Oliveira Rodrigues.
Arq. Asma, Alerg. Imunol ; 6(2): 295-299, abr.jun.2022. ilus
Artículo en Inglés, Portugués | LILACS | ID: biblio-1400226

Documentos relacionados

  1. Single-cell profiling identifies mechanisms of inflammatory heterogeneity in chronic rhinosinusitis.
  2. A Decade of Pathogenesis Advances in Non-Type 2 Inflammatory Endotypes in Chronic Rhinosinusitis: 2012-2022.
  3. The percentage of controlled chronic rhinosinusitis after treatment: a systematic review and meta-analysis.
  4. Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches.
  5. [Regulatory dysfunctions in nasal polyposis].
  6. EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care.
  7. Dupilumab for chronic rhinosinusitis with nasal polyps: real-life retrospective 12-month effectiveness data.
  8. Residual nasal polyp tissue following dupilumab therapy is associated with periostin-associated fibrosis.
  9. [Dynamic monitoring of patients with chronic rhinosinusitis with nasal polyps].
  10. Neurohormonal markers in chronic rhinosinusitis.